329 related articles for article (PubMed ID: 37133853)
1. Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.
Dillman RO; Nistor GI; Keirstead HS
Hum Vaccin Immunother; 2023 Dec; 19(1):2198467. PubMed ID: 37133853
[TBL] [Abstract][Full Text] [Related]
2. Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.
Dillman RO; McClay EF; Barth NM; Amatruda TT; Schwartzberg LS; Mahdavi K; de Leon C; Ellis RE; DePriest C
Cancer Biother Radiopharm; 2015 Jun; 30(5):187-94. PubMed ID: 26083950
[TBL] [Abstract][Full Text] [Related]
3. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
5. Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine.
Dillman RO; Nistor GI; Poole AJ
Hum Vaccin Immunother; 2020 Apr; 16(4):742-755. PubMed ID: 31625825
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
8. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
9. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Dillman RO; Cornforth AN; Nistor GI; McClay EF; Amatruda TT; Depriest C
J Immunother Cancer; 2018 Mar; 6(1):19. PubMed ID: 29510745
[TBL] [Abstract][Full Text] [Related]
11. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study.
de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M
J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma.
Wang X; Bayer ME; Chen X; Fredrickson C; Cornforth AN; Liang G; Cannon J; He J; Fu Q; Liu J; Nistor GI; Cao W; Chen C; Dillman RO
J Surg Oncol; 2015 Jun; 111(7):862-7. PubMed ID: 25873455
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma.
Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ
J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
20. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
